P
PepGen
Biotech & Life Sciences · Cambridge, United States · Founded 2018 · IPO 2022
Transforming the Treatment of Neuromuscular Diseases MoreLess
PepGen is a biotechnology company focused on developing advanced nucleic acid therapeutics using its proprietary peptide technology. The company collaborates with researchers and medical institutions to address complex medical conditions, including Duchenne and Becker muscular dystrophy. Operating primarily in the biopharmaceutical market, PepGen serves healthcare providers and research organizations. Its business model involves both independent and partnered development pathways, generating revenue through research collaborations, licensing agreements, and potential future sales of therapeutic products. The company aims to revolutionize the delivery of nucleic acid-based drugs, enhancing their efficacy and reach.
Keywords: peptide technology, nucleic acid therapeutics, biotechnology, drug delivery, Duchenne muscular dystrophy, Becker muscular dystrophy, biopharmaceutical, research collaboration, licensing agreements, therapeutic products.
Company overview
PepGen company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- Cambridge, United States
- Employees
- 64
- Open positions
- None listed
- Dealroom signal
- 64.7
Valuation & funding
PepGen funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Feb 2026 | $115M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Sep 2025 | $0 | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Feb 2024 | $80M | — | Adage Capital · Frazier Healthcare Partners · RA Capital Management · Perceptive Advisors | ↗ |
| IPOOther financing | May 2022 | $108M | $108M | Undisclosed | ↗ |
| LATE VCOther financing | Aug 2021 | $113M | $450M | Deerfield · Viking Global Investors · Samsara BioCapital · Tudor Group | — |
| SERIES AOther financing | Dec 2020 | Oxford Science Enterprises · Cure Duchenne · RA Capital Management | — | ||
| GRANTOther financing | Nov 2018 | Undisclosed | — | ||
| SEEDOther financing | Mar 2018 | Oxford Science Enterprises | — | ||
| SPINOUTOther financing | Jan 2018 | Oxford University Innovation · University of Oxford | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$88M | — |
| 2025 | $0 | — | −$88M | — |
| 2024 | $0 | — | −$92M | — |
| 2023 | $0 | — | −$84M | — |
| 2022 | $0 | — | −$68M | — |
| 2021 | $0 | — | −$27M | — |
| 2020 | $0 | — | −$1.8M | — |
Growth signals
PepGen website traffic
Latest recorded traffic for PepGen is 4.7K monthly website visits, down 7.8% over the last three months. PepGen's team declined 3% over the past year.
Hiring
Open positions at PepGen
Current openings linked to this company in Dealroom.
Comparisons
PepGen compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
PepGen's talent
Source: Dealroom Talent Intelligence.
Investors
19 investors on PepGen's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where PepGen has talent and traffic
team presence
In the news
Latest news about PepGen
Recent press, funding announcements, and product moves mentioning PepGen — open to read from the original sources.
Market sentiment
What the market is saying about PepGen
An AI-synthesized read of the highest-engagement posts about PepGen on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PepGen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.